{"ticker": {"uuid": "f585907f-e583-4c83-8f6c-f4508f6a9526", "symbol": "GLSI", "name": "Greenwich Lifesciences\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Greenwich LifeSciences Says EU Regulator Approves Combination of HLA Patients in Phase 3 Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/greenwich-lifesciences-says-eu-regulator-121527043.html", "source_name": "MT Newswires", "published_at": "2026-07-16T12:15:27+00:00", "published_display": "16 Jul 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences expands trial enrollment in Europe By Investing.com", "summary": "Greenwich LifeSciences (NASDAQ:GLSI) has announced that the European Medicines Agency approved the inclusion of both HLA-A02 and non-HLA-A02 patients in its FLAMINGO-01 Phase III clinical trial, aligning European and U.S. protocols. The company, which is evaluating GLSI-100 to pr", "url": "https://m.au.investing.com/news/stock-market-news/greenwich-lifesciences-expands-trial-enrollment-in-europe-93CH-4536627?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-16T12:10:10", "published_display": "16 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Announces European Approval For Combining Both HLA Populations In FLAMINGO-01", "summary": "Greenwich LifeSciences has received European Medicines Agency (EMA) approval to combine both HLA-A*02 and non-HLA-A*02 patient populations in its FLAMINGO-01 clinical trial, mirroring a prior FDA approval. This change standardizes the protocol across US and European sites, potent", "url": "https://www.marketscreener.com/news/greenwich-lifesciences-announces-european-approval-for-combining-both-hla-populations-in-flamingo-01-ce7f5ed3d888f52d", "source_name": "www.marketscreener.com", "published_at": "2026-07-16T12:10:10", "published_display": "16 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A breast cancer trial can now enroll patients who waited up to a year", "summary": "Greenwich LifeSciences (Nasdaq: GLSI) announced that the European Medicines Agency (EMA) has approved combining both HLA-A*02 and non-HLA-A*02 patients in the randomized arms of its Phase III FLAMINGO-01 trial for GLSI-100, which aims to prevent breast cancer recurrences. This de", "url": "https://www.stocktitan.net/news/GLSI/greenwich-life-sciences-announces-european-approval-for-combining-skh30o2kq89h.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:10:10", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences The Overlooked Need (NASDAQ:GLSI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPYkJxWU51Yl9pOC1xSlptbTEzY0V0dWNETjdQWFl0bGJxSHdiNk9VM0s5b0kwbjRjdFBycHB6VEpqZXQxZGNHNDNFZWdQV3JmZ1ZKcFcyNmVYOTZXNFM3YS1ZVDJTMVE4YkJNaGN1ZmMxTlpIVGtKM0dNTzJVbi1yRjl0eHk2WVZjdWgzdGFn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-16T07:33:08+00:00", "published_display": "16 Jul 2026 07:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Greenwich Lifesciences Inc announced that its commercial production of Gp2 has been approved for use in the Flamingo-01 study in Europe.", "summary": "Greenwich Lifesciences Inc. has announced that its Gp2 commercial production has received approval for use in the Flamingo-01 study in Europe. This approval signifies a key regulatory achievement for the company as it advances its primary candidate products. The announcement was ", "url": "https://www.bitget.com/amp/news/detail/12560605497574", "source_name": "Bitget", "published_at": "2026-07-10T05:12:12", "published_display": "10 Jul 2026 05:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01", "summary": "Greenwich LifeSciences (GLSI) announced European approval for the use of commercially manufactured GP2 in its FLAMINGO-01 Phase III clinical trial, following prior U.S. approval. All clinical sites across the U.S. and Europe will now use the same commercial lot of GP2 vials to tr", "url": "https://www.globenewswire.com/news-release/2026/07/09/3324636/0/en/greenwich-lifesciences-announces-european-approval-for-use-of-commercially-manufactured-gp2-in-flamingo-01.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T04:09:26", "published_display": "10 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Receives European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01", "summary": "Greenwich Lifesciences has received European Medicines Agency (EMA) approval to use its commercially manufactured GP2 lot in the FLAMINGO-01 clinical trial in Europe, following prior FDA approval for its use in the US. This means all US and European clinical sites, now numbering ", "url": "https://www.marketscreener.com/news/greenwich-lifesciences-receives-european-approval-for-use-of-commercially-manufactured-gp2-in-flamin-ce7f5ededa8ef722", "source_name": "marketscreener.com", "published_at": "2026-07-09T18:03:28", "published_display": "09 Jul 2026 18:03", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences stock jumps as EMA approves commercial GP2", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOTEJTYUppMmloR01xR1VtSVV3RHpBaTRLUk4wWnNFc0g4d2FUa05XcWNvSEFZbENVMldCSkVPLWhudDVTUVRfSjJCR1R5R3ZSYmlfWWlhN1JMV2k2R1QtMEpkX1BwSUU1Qjc5aXQ2aFRIRjY4U2xBaXF5MERUZjBDWXBEc1RnV2ptZ3N5ekZ2MnpXVTFCM1VWZFhfNFNuMWFyWnRYVnJIQ0YwYWpLU1U5YzM5c2x0R0RlR0UwbndIb0tid094S0E?oc=5", "source_name": "Investing.com", "published_at": "2026-07-09T15:54:02+00:00", "published_display": "09 Jul 2026 15:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences stock jumps as EMA approves commercial GP2 By Investing.com", "summary": "Greenwich LifeSciences (NASDAQ:GLSI) shares increased by 7.7% after the European Medicines Agency (EMA) approved the commercial manufacture of GP2 for use in its FLAMINGO-01 clinical trial. This approval allows clinical sites in both the US and Europe to use the same GP2 lot, wit", "url": "https://m.za.investing.com/news/stock-market-news/greenwich-lifesciences-stock-jumps-as-ema-approves-commercial-gp2-93CH-4363057?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-09T16:03:28", "published_display": "09 Jul 2026 16:03", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Says Commercially Manufactured GP2 Cleared for Trial in Europe", "summary": "Greenwich LifeSciences announced that its commercially manufactured GP2 immunotherapy has been cleared for clinical trial in Europe. This marks a significant step towards global distribution and supports the company's planned Phase III trial in Europe for breast cancer patients. ", "url": "https://www.moomoo.com/news/post/72710919/greenwich-lifesciences-says-commercially-manufactured-gp2-cleared-for-trial-in?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T11:03:27", "published_display": "09 Jul 2026 11:03", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Secures EMA Approval for Phase 3 GP2 Lot", "summary": "Greenwich LifeSciences (NASDAQ:GLSI) has received European Medicines Agency (EMA) approval for its commercially manufactured GP2 immunotherapy lot for the Phase III FLAMINGO-01 clinical trial, standardizing the global supply chain after prior FDA approval. This approval allows fo", "url": "https://grafa.com/en/news/united-states/greenwich-lifesciences-ema-approval-gp2-flamingo-01", "source_name": "grafa.com", "published_at": "2026-07-09T10:15:00", "published_display": "09 Jul 2026 10:15", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Europe joins U.S. in using commercial GP2 for Greenwich\u2019s breast cancer trial", "summary": "Greenwich LifeSciences (GLSI) announced that the European Medicines Agency (EMA) has approved the use of its commercially manufactured GP2 lot in the Phase III FLAMINGO-01 breast cancer trial. This approval follows earlier clearance from the FDA for use in the U.S., meaning all 1", "url": "https://www.stocktitan.net/news/GLSI/greenwich-life-sciences-announces-european-approval-for-use-of-nbiuu2e91zfc.html", "source_name": "Stock Titan", "published_at": "2026-07-09T10:10:56", "published_display": "09 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (GLSI) That Institutions Follow", "summary": "This article analyzes Greenwich Lifesciences Inc. (NASDAQ: GLSI), highlighting weak near and mid-term sentiment which could challenge its long-term positive outlook. It provides technical signals, institutional trading strategies (position, momentum, risk hedging), and multi-time", "url": "https://news.stocktradersdaily.com/news_release/9/The_Technical_Signals_Behind_GLSI_That_Institutions_Follow_070726061402_1783462442.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-07T18:14:00", "published_display": "07 Jul 2026 18:14", "sentiment": "negative", "sentiment_pct": 35, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLSI - Greenwich LifeSciences Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Greenwich LifeSciences Inc (GLSI). It includes key financial metrics, stock performance, insider ownership, institutional ownership, and analyst recommendations, offering a detailed snapshot of the ", "url": "https://finviz.com/stock?t=GLSI&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-05T02:40:49", "published_display": "05 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLSI - Greenwich LifeSciences Inc Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for Greenwich LifeSciences Inc (GLSI), including its stock performance, market capitalization, income, sales, and various financial ratios. It highlights key metrics such as insider ownership, institutional ownership, volatilit", "url": "https://finviz.com/stock?t=GLSI&ty=rv&p=m&b=1", "source_name": "Finviz", "published_at": "2026-07-04T04:09:20", "published_display": "04 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLSI - Greenwich LifeSciences Inc Options", "summary": "This article provides a detailed financial overview of Greenwich LifeSciences Inc (GLSI), including its recent stock performance, key financial metrics, ownership data, and various valuation ratios. The company's stock closed at $22.00, experiencing a 7.17% decrease. It also high", "url": "https://finviz.com/stock?t=GLSI&ty=oc&p=m&b=1", "source_name": "Finviz", "published_at": "2026-07-04T02:10:19", "published_display": "04 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GREENWICH LIFESCIENCES INC (GLSI) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE8tYm15MEVQV1hBdE5VeUl3N3pTQ0pjMlIxcWVILWw5eTFXMFJZcVVGd1pTd1JaWkI3TWdaLVRKM2FHYVRnVk52VGRHckJBRGNQempETnprQlBydEZ2ZEpPa2g4a1k?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:01+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a compilation of Greenwich LifeSciences, Inc.'s financial disclosures and SEC filings, including quarterly and annual reports detailing net losses, R&D spending, and cash positions. It also mentions key corporate events such as conference presentations and u", "url": "https://www.tradingview.com/symbols/NASDAQ-GLSI/documents/", "source_name": "TradingView", "published_at": "2026-07-02T18:39:59", "published_display": "02 Jul 2026 18:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Greenwich LifeSciences, Inc. \u2013 NASDAQ:GLSI", "summary": "This article provides \"Price to book forward\" information for Greenwich LifeSciences, Inc. (NASDAQ:GLSI). It appears to be a financial data point presented on the TradingView platform, noting that the market is closed with no trades. The minimal content suggests this is primarily", "url": "https://www.tradingview.com/symbols/NASDAQ-GLSI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:39:34", "published_display": "28 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Greenwich Lifesciences Inc. (GLSI) Risk Zones", "summary": "This article from Stock Traders Daily provides a detailed analysis of Greenwich Lifesciences Inc. (GLSI), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It outlines several AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk ", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Greenwich_Lifesciences_Inc._GLSI_Risk_Zones_062626050602_1782507962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-27T13:13:34", "published_display": "27 Jun 2026 13:13", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Greenwich LifeSciences, Inc. \u2013 NASDAQ:GLSI", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for Greenwich LifeSciences, Inc. (NASDAQ: GLSI). The content is minimal, essentially displaying the company's stock ticker and market information. It indicates that the market is closed with no current ", "url": "https://www.tradingview.com/symbols/NASDAQ-GLSI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:39:09", "published_display": "25 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Greenwich LifeSciences, Inc. \u2013 NASDAQ:GLSI", "summary": "This article focuses on the enterprise value to EBIT forward for Greenwich LifeSciences, Inc. (NASDAQ: GLSI). The content appears to be a financial data page from TradingView, providing an overview of the company's financial metrics within the Biotechnology sector. It highlights ", "url": "https://www.tradingview.com/symbols/NASDAQ-GLSI/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:57", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Greenwich Lifesciences Inc (GLSI), noting its strong financial status and low operating efficiency, with a current financial score of 6.92. It ranks 187 out of 388 in the Biotechnology & Medical Research industry. The report highlight", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T09:09:24", "published_display": "18 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Greenwich Lifesciences Inc (GLSI) has an earnings forecast score of 8.00, placing it 165th in the Biotechnology & Medical Research industry. Analysts project an average price target of $42.00, with a consensus \"Buy\" rating based on two analysts. The company's EPS for the previous", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T07:14:55", "published_display": "18 Jun 2026 07:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Greenwich Lifesciences Inc (GLSI) focusing on its dividend history and stock splits. It notes that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also presents current stock da", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:41:14", "published_display": "17 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Institutional Confidence", "summary": "Greenwich Lifesciences Inc (GLSI) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 19.42% quarter-over-quarter to 11.38%. Patel (Snehal) is the lar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T19:09:24", "published_display": "17 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Greenwich Lifesciences Inc (GLSI) by business segment and region. However, it explicitly states that the relevant data for such a breakdown has not been disclosed by the company yet. The page primarily displ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:09", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Greenwich Lifesciences Inc (GLSI), outlining both major individual and institutional holdings. It provides a breakdown of shareholder types, including individual investors, investment advisors, and hedge funds, along with a histor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:09", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLSI Stock News Today | Earnings, Events & Price Alerts", "summary": "Greenwich LifeSciences (GLSI) has provided updates on its clinical trials and financial reporting. The company presented positive Phase 3 data for its breast cancer vaccine at the ASCO Annual Meeting, showing a significant increase in immune responses. GLSI also addressed delays ", "url": "https://intellectia.ai/en/stock/GLSI/news", "source_name": "Intellectia AI", "published_at": "2026-06-16T19:09:24", "published_display": "16 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to GLSI Trends in Macro Strategies", "summary": "This article provides a technical analysis of Greenwich Lifesciences Inc. (NASDAQ: GLSI), highlighting a positive near-term sentiment within a long-term strong context. It details institutional trading strategies, including position trading, momentum breakout, and risk hedging, b", "url": "https://news.stocktradersdaily.com/news_release/12/Technical_Reactions_to_GLSI_Trends_in_Macro_Strategies_061526035401_1781553241.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T15:54:00", "published_display": "15 Jun 2026 15:54", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026", "summary": "Greenwich LifeSciences, Inc. presented open-label data from its FLAMINGO-01 Phase III trial at the ASCO Annual Meeting 2026, showcasing statistically significant increased injection site reaction (ISR) immune responses in non-HLA-A*02 breast cancer patients treated with GLSI-100.", "url": "https://www.globenewswire.com/news-release/2026/6/1/3304343/0/en/greenwich-lifesciences-presents-flamingo-01-phase-iii-trial-open-label-data-published-at-asco-meeting-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-06T14:44:52", "published_display": "06 Jun 2026 14:44", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences, Inc. Q1 2026 Quarterly Report: Financials, Risk Factors, and Disclosure Highlights", "summary": "Greenwich LifeSciences (GLSI) released its Q1 2026 unaudited financial statements, showing a sharp increase in net loss to $5.6 million due to higher clinical trial expenses. The company successfully raised capital through ATM offerings, but also disclosed material weaknesses in ", "url": "https://www.minichart.com.sg/2026/06/05/greenwich-lifesciences-inc-q1-2026-quarterly-report-financials-risk-factors-and-disclosure-highlights/", "source_name": "Minichart", "published_at": "2026-06-05T00:36:15", "published_display": "05 Jun 2026 00:36", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/greenwich-lifesciences-says-audit-2025-104846963.html", "source_name": "MT Newswires", "published_at": "2026-06-01T10:48:46+00:00", "published_display": "01 Jun 2026 10:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Provides Update Regarding Form 10-K Filing", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/greenwich-lifesciences-provides-regarding-form-100000046.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T10:00:00+00:00", "published_display": "01 Jun 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GREENWICH LIFESCIENCES ($GLSI) Releases Q4 2025 Earnings | GLSI Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPMTQ5SWdHY3FCVUhQb1BiQUp4d2lMRVhRVnpsZ0dUWEhwTmFHUHJGYzRjNm1ZWVdYQzBxMzVJR2oxR0dJN3p1QlRYUWhLZV8tVldMeDdDQk50eDRpVWVtR0h1bDI1MmZaWkE0NVRTc1dLbjh2bUdUM1M0LTltN2YxYWJNazRHZkppMExVZHRFb0NKR0ZNQVYtMHJCVQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOeTdPY1hMcGFJcjI3OFdTLWJJUmsyV0IzWTRlZ0Y5dUNnUzRBaEZKQ2VlZ1d1c1MxMTl6VE9qOXJNWWhrOTJYanp0NVAxZ0NONHhjeFJWbHUxYVlDV05kNzVsMkFwT1JyeU1mLURubVFsR0s5ZkZ6UUdZcjRqZVZqdHBGSGk2aGMtUEN2VGhFcUZrOUhQbjM1UlBPbng0TnpoU3c0UnRzUi1NaXVJYXRLSjZWeEZLbFotTE5OaExyRWtUVkJxTkpBX2pTMHB6cld2aHdpLVNORHNpN1E0Uzl5dmtwU3VVOVFERmlzQ0hmWHhUaXc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNa01PSE9fVlh1NGl0YXBRN1JuOHlZRm1XdS1YajRhWmNwT0NGc21OZkMwcXc0bWxOWjlSQVNLXzFKeGJBdW16RFNidXNEN0tvOUFNUXhybnp4d01TSm9uSTVyc2M4X0hWcmRrck9Db1cyazA3RkNXUm9ZMmdlTmljbVJKTWh0ODRDYTVTZ25LdVhTbTQwUHFtMDBUMC1ONGlLcHRGUEk4YTRmQW1oWmV2VExQLXZ0eGM?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQMWxOUjMxdXBOTDdVV1YzeTYyWmZ2M2l3R19IOGNHWk52SDYxMXhKUWZsc3BHaTdETFdPbTZkUk5QbXJzUmRlTm91ZjRXVFZaWGxKQ3l5b2pud3FqVERnMGhIdi16bldidUZwNUlFX2gtV01BSk9ySHk2ZGhWclBEeE5NdmNNN1pQS2FMU0plS1ZzMEpvZUdHQjZ1WFhLc2MwblZaZnZEMm16WjRtUF9r?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FDA approves commercial GP2 lot for Greenwich\u2019s breast cancer trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNSUtkOHc4ZVcxNFlYTmIzLTVlUlVoeW5FcDVlVVVfUzZvWDBrQlF3NHNLZS1SMkFPT3ZCYlRqMHJRZTJ6cDZ3aXdnMjFLYmRTRE0tUnhrd3lBRW5xN2ZNZGh2TDF5eURJczNyeHJKSGFjUk5wMl9FWUJYbkpBQ1hBdGRRb0l0UVB2azFLZ0tEbnA5YWN0QkE4dVZ4cE8xa2hBQ1JJUno5bVBzemxMNVJPeTJTN0dXMzhGcTUwUzB1Rlg?oc=5", "source_name": "Investing.com", "published_at": "2026-01-22T08:00:00+00:00", "published_display": "22 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Snehal Patel Buys Handful Of Shares In Greenwich LifeSciences", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences, Inc. Announces Extension of Lock-Up Period for Shares to September 30, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQYlFKYVYtZHpFSnpfNWlOTng1alVpZ3JwcWgzdjBsOEtLbXFVUzJqV0VoMzZaQUJRdk5wc1VpTWhLUHIxbm11TnFvMFlrdUVVLWdZVmRzN0lTQkxweloxZUVtTG14VzNJQUFOVHd5MTBRUE9SRWFfdnFPQ2ozTlc2aFZiTHRyU3o4ZGVYWHBabkx3WGZYOWxTdm5Ba05nak8wdElqOGJ5M2ZDbWwydG1zbUd3VWZYQzRESEQzQktGRGtOYjRpTHI5NWowTURtcEw4MHc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQT1F5YmFzejhtbFhVQUo2R0x5YURONU1pWlJWOGtmUXJLeGFGaFQtb0RTU0l4U2dlbDl2VTI5RzBiMVNLMTZsZTJhNnVpWFFNX2l5Q0FhdFMyR1MxMjYxdzJSbGVRNC0wSFpjWXR6UFk0Yk5hSFNvbmlkd1ZncUZkZGJROFJMTDlpVWpzYlhXWnI3VzVPQ0szLUlOc1lLWGJKMGhQUmYzM0QwVHllMlFVUDJabW1hSFpaeElNRHZsc0Y?oc=5", "source_name": "Stock Titan", "published_at": "2024-03-13T07:00:00+00:00", "published_display": "13 Mar 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Greenwich LifeSciences Says EU Regulator Approves Combination of HLA Patients in Phase 3 Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/greenwich-lifesciences-says-eu-regulator-121527043.html", "source_name": "MT Newswires", "published_at": "2026-07-16T12:15:27+00:00", "published_display": "16 Jul 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences expands trial enrollment in Europe By Investing.com", "summary": "Greenwich LifeSciences (NASDAQ:GLSI) has announced that the European Medicines Agency approved the inclusion of both HLA-A02 and non-HLA-A02 patients in its FLAMINGO-01 Phase III clinical trial, aligning European and U.S. protocols. The company, which is evaluating GLSI-100 to pr", "url": "https://m.au.investing.com/news/stock-market-news/greenwich-lifesciences-expands-trial-enrollment-in-europe-93CH-4536627?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-16T12:10:10", "published_display": "16 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Announces European Approval For Combining Both HLA Populations In FLAMINGO-01", "summary": "Greenwich LifeSciences has received European Medicines Agency (EMA) approval to combine both HLA-A*02 and non-HLA-A*02 patient populations in its FLAMINGO-01 clinical trial, mirroring a prior FDA approval. This change standardizes the protocol across US and European sites, potent", "url": "https://www.marketscreener.com/news/greenwich-lifesciences-announces-european-approval-for-combining-both-hla-populations-in-flamingo-01-ce7f5ed3d888f52d", "source_name": "www.marketscreener.com", "published_at": "2026-07-16T12:10:10", "published_display": "16 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A breast cancer trial can now enroll patients who waited up to a year", "summary": "Greenwich LifeSciences (Nasdaq: GLSI) announced that the European Medicines Agency (EMA) has approved combining both HLA-A*02 and non-HLA-A*02 patients in the randomized arms of its Phase III FLAMINGO-01 trial for GLSI-100, which aims to prevent breast cancer recurrences. This de", "url": "https://www.stocktitan.net/news/GLSI/greenwich-life-sciences-announces-european-approval-for-combining-skh30o2kq89h.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:10:10", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences The Overlooked Need (NASDAQ:GLSI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPYkJxWU51Yl9pOC1xSlptbTEzY0V0dWNETjdQWFl0bGJxSHdiNk9VM0s5b0kwbjRjdFBycHB6VEpqZXQxZGNHNDNFZWdQV3JmZ1ZKcFcyNmVYOTZXNFM3YS1ZVDJTMVE4YkJNaGN1ZmMxTlpIVGtKM0dNTzJVbi1yRjl0eHk2WVZjdWgzdGFn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-16T07:33:08+00:00", "published_display": "16 Jul 2026 07:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc announced that its commercial production of Gp2 has been approved for use in the Flamingo-01 study in Europe.", "summary": "Greenwich Lifesciences Inc. has announced that its Gp2 commercial production has received approval for use in the Flamingo-01 study in Europe. This approval signifies a key regulatory achievement for the company as it advances its primary candidate products. The announcement was ", "url": "https://www.bitget.com/amp/news/detail/12560605497574", "source_name": "Bitget", "published_at": "2026-07-10T05:12:12", "published_display": "10 Jul 2026 05:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01", "summary": "Greenwich LifeSciences (GLSI) announced European approval for the use of commercially manufactured GP2 in its FLAMINGO-01 Phase III clinical trial, following prior U.S. approval. All clinical sites across the U.S. and Europe will now use the same commercial lot of GP2 vials to tr", "url": "https://www.globenewswire.com/news-release/2026/07/09/3324636/0/en/greenwich-lifesciences-announces-european-approval-for-use-of-commercially-manufactured-gp2-in-flamingo-01.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T04:09:26", "published_display": "10 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Receives European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01", "summary": "Greenwich Lifesciences has received European Medicines Agency (EMA) approval to use its commercially manufactured GP2 lot in the FLAMINGO-01 clinical trial in Europe, following prior FDA approval for its use in the US. This means all US and European clinical sites, now numbering ", "url": "https://www.marketscreener.com/news/greenwich-lifesciences-receives-european-approval-for-use-of-commercially-manufactured-gp2-in-flamin-ce7f5ededa8ef722", "source_name": "marketscreener.com", "published_at": "2026-07-09T18:03:28", "published_display": "09 Jul 2026 18:03", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences stock jumps as EMA approves commercial GP2", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOTEJTYUppMmloR01xR1VtSVV3RHpBaTRLUk4wWnNFc0g4d2FUa05XcWNvSEFZbENVMldCSkVPLWhudDVTUVRfSjJCR1R5R3ZSYmlfWWlhN1JMV2k2R1QtMEpkX1BwSUU1Qjc5aXQ2aFRIRjY4U2xBaXF5MERUZjBDWXBEc1RnV2ptZ3N5ekZ2MnpXVTFCM1VWZFhfNFNuMWFyWnRYVnJIQ0YwYWpLU1U5YzM5c2x0R0RlR0UwbndIb0tid094S0E?oc=5", "source_name": "Investing.com", "published_at": "2026-07-09T15:54:02+00:00", "published_display": "09 Jul 2026 15:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences stock jumps as EMA approves commercial GP2 By Investing.com", "summary": "Greenwich LifeSciences (NASDAQ:GLSI) shares increased by 7.7% after the European Medicines Agency (EMA) approved the commercial manufacture of GP2 for use in its FLAMINGO-01 clinical trial. This approval allows clinical sites in both the US and Europe to use the same GP2 lot, wit", "url": "https://m.za.investing.com/news/stock-market-news/greenwich-lifesciences-stock-jumps-as-ema-approves-commercial-gp2-93CH-4363057?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-09T16:03:28", "published_display": "09 Jul 2026 16:03", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Says Commercially Manufactured GP2 Cleared for Trial in Europe", "summary": "Greenwich LifeSciences announced that its commercially manufactured GP2 immunotherapy has been cleared for clinical trial in Europe. This marks a significant step towards global distribution and supports the company's planned Phase III trial in Europe for breast cancer patients. ", "url": "https://www.moomoo.com/news/post/72710919/greenwich-lifesciences-says-commercially-manufactured-gp2-cleared-for-trial-in?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T11:03:27", "published_display": "09 Jul 2026 11:03", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Secures EMA Approval for Phase 3 GP2 Lot", "summary": "Greenwich LifeSciences (NASDAQ:GLSI) has received European Medicines Agency (EMA) approval for its commercially manufactured GP2 immunotherapy lot for the Phase III FLAMINGO-01 clinical trial, standardizing the global supply chain after prior FDA approval. This approval allows fo", "url": "https://grafa.com/en/news/united-states/greenwich-lifesciences-ema-approval-gp2-flamingo-01", "source_name": "grafa.com", "published_at": "2026-07-09T10:15:00", "published_display": "09 Jul 2026 10:15", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Europe joins U.S. in using commercial GP2 for Greenwich\u2019s breast cancer trial", "summary": "Greenwich LifeSciences (GLSI) announced that the European Medicines Agency (EMA) has approved the use of its commercially manufactured GP2 lot in the Phase III FLAMINGO-01 breast cancer trial. This approval follows earlier clearance from the FDA for use in the U.S., meaning all 1", "url": "https://www.stocktitan.net/news/GLSI/greenwich-life-sciences-announces-european-approval-for-use-of-nbiuu2e91zfc.html", "source_name": "Stock Titan", "published_at": "2026-07-09T10:10:56", "published_display": "09 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (GLSI) That Institutions Follow", "summary": "This article analyzes Greenwich Lifesciences Inc. (NASDAQ: GLSI), highlighting weak near and mid-term sentiment which could challenge its long-term positive outlook. It provides technical signals, institutional trading strategies (position, momentum, risk hedging), and multi-time", "url": "https://news.stocktradersdaily.com/news_release/9/The_Technical_Signals_Behind_GLSI_That_Institutions_Follow_070726061402_1783462442.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-07T18:14:00", "published_display": "07 Jul 2026 18:14", "sentiment": "negative", "sentiment_pct": 35, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLSI - Greenwich LifeSciences Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Greenwich LifeSciences Inc (GLSI). It includes key financial metrics, stock performance, insider ownership, institutional ownership, and analyst recommendations, offering a detailed snapshot of the ", "url": "https://finviz.com/stock?t=GLSI&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-05T02:40:49", "published_display": "05 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLSI - Greenwich LifeSciences Inc Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for Greenwich LifeSciences Inc (GLSI), including its stock performance, market capitalization, income, sales, and various financial ratios. It highlights key metrics such as insider ownership, institutional ownership, volatilit", "url": "https://finviz.com/stock?t=GLSI&ty=rv&p=m&b=1", "source_name": "Finviz", "published_at": "2026-07-04T04:09:20", "published_display": "04 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLSI - Greenwich LifeSciences Inc Options", "summary": "This article provides a detailed financial overview of Greenwich LifeSciences Inc (GLSI), including its recent stock performance, key financial metrics, ownership data, and various valuation ratios. The company's stock closed at $22.00, experiencing a 7.17% decrease. It also high", "url": "https://finviz.com/stock?t=GLSI&ty=oc&p=m&b=1", "source_name": "Finviz", "published_at": "2026-07-04T02:10:19", "published_display": "04 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GREENWICH LIFESCIENCES INC (GLSI) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE8tYm15MEVQV1hBdE5VeUl3N3pTQ0pjMlIxcWVILWw5eTFXMFJZcVVGd1pTd1JaWkI3TWdaLVRKM2FHYVRnVk52VGRHckJBRGNQempETnprQlBydEZ2ZEpPa2g4a1k?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:01+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a compilation of Greenwich LifeSciences, Inc.'s financial disclosures and SEC filings, including quarterly and annual reports detailing net losses, R&D spending, and cash positions. It also mentions key corporate events such as conference presentations and u", "url": "https://www.tradingview.com/symbols/NASDAQ-GLSI/documents/", "source_name": "TradingView", "published_at": "2026-07-02T18:39:59", "published_display": "02 Jul 2026 18:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Greenwich LifeSciences, Inc. \u2013 NASDAQ:GLSI", "summary": "This article provides \"Price to book forward\" information for Greenwich LifeSciences, Inc. (NASDAQ:GLSI). It appears to be a financial data point presented on the TradingView platform, noting that the market is closed with no trades. The minimal content suggests this is primarily", "url": "https://www.tradingview.com/symbols/NASDAQ-GLSI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:39:34", "published_display": "28 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Greenwich Lifesciences Inc. (GLSI) Risk Zones", "summary": "This article from Stock Traders Daily provides a detailed analysis of Greenwich Lifesciences Inc. (GLSI), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It outlines several AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk ", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Greenwich_Lifesciences_Inc._GLSI_Risk_Zones_062626050602_1782507962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-27T13:13:34", "published_display": "27 Jun 2026 13:13", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Greenwich LifeSciences, Inc. \u2013 NASDAQ:GLSI", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for Greenwich LifeSciences, Inc. (NASDAQ: GLSI). The content is minimal, essentially displaying the company's stock ticker and market information. It indicates that the market is closed with no current ", "url": "https://www.tradingview.com/symbols/NASDAQ-GLSI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:39:09", "published_display": "25 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Greenwich LifeSciences, Inc. \u2013 NASDAQ:GLSI", "summary": "This article focuses on the enterprise value to EBIT forward for Greenwich LifeSciences, Inc. (NASDAQ: GLSI). The content appears to be a financial data page from TradingView, providing an overview of the company's financial metrics within the Biotechnology sector. It highlights ", "url": "https://www.tradingview.com/symbols/NASDAQ-GLSI/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:57", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Greenwich Lifesciences Inc (GLSI), noting its strong financial status and low operating efficiency, with a current financial score of 6.92. It ranks 187 out of 388 in the Biotechnology & Medical Research industry. The report highlight", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T09:09:24", "published_display": "18 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Greenwich Lifesciences Inc (GLSI) has an earnings forecast score of 8.00, placing it 165th in the Biotechnology & Medical Research industry. Analysts project an average price target of $42.00, with a consensus \"Buy\" rating based on two analysts. The company's EPS for the previous", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T07:14:55", "published_display": "18 Jun 2026 07:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Greenwich Lifesciences Inc (GLSI) focusing on its dividend history and stock splits. It notes that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also presents current stock da", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:41:14", "published_display": "17 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Institutional Confidence", "summary": "Greenwich Lifesciences Inc (GLSI) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 19.42% quarter-over-quarter to 11.38%. Patel (Snehal) is the lar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T19:09:24", "published_display": "17 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Greenwich Lifesciences Inc (GLSI) by business segment and region. However, it explicitly states that the relevant data for such a breakdown has not been disclosed by the company yet. The page primarily displ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:09", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich Lifesciences Inc (GLSI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Greenwich Lifesciences Inc (GLSI), outlining both major individual and institutional holdings. It provides a breakdown of shareholder types, including individual investors, investment advisors, and hedge funds, along with a histor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-glsi/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:09", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLSI Stock News Today | Earnings, Events & Price Alerts", "summary": "Greenwich LifeSciences (GLSI) has provided updates on its clinical trials and financial reporting. The company presented positive Phase 3 data for its breast cancer vaccine at the ASCO Annual Meeting, showing a significant increase in immune responses. GLSI also addressed delays ", "url": "https://intellectia.ai/en/stock/GLSI/news", "source_name": "Intellectia AI", "published_at": "2026-06-16T19:09:24", "published_display": "16 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to GLSI Trends in Macro Strategies", "summary": "This article provides a technical analysis of Greenwich Lifesciences Inc. (NASDAQ: GLSI), highlighting a positive near-term sentiment within a long-term strong context. It details institutional trading strategies, including position trading, momentum breakout, and risk hedging, b", "url": "https://news.stocktradersdaily.com/news_release/12/Technical_Reactions_to_GLSI_Trends_in_Macro_Strategies_061526035401_1781553241.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T15:54:00", "published_display": "15 Jun 2026 15:54", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026", "summary": "Greenwich LifeSciences, Inc. presented open-label data from its FLAMINGO-01 Phase III trial at the ASCO Annual Meeting 2026, showcasing statistically significant increased injection site reaction (ISR) immune responses in non-HLA-A*02 breast cancer patients treated with GLSI-100.", "url": "https://www.globenewswire.com/news-release/2026/6/1/3304343/0/en/greenwich-lifesciences-presents-flamingo-01-phase-iii-trial-open-label-data-published-at-asco-meeting-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-06T14:44:52", "published_display": "06 Jun 2026 14:44", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences, Inc. Q1 2026 Quarterly Report: Financials, Risk Factors, and Disclosure Highlights", "summary": "Greenwich LifeSciences (GLSI) released its Q1 2026 unaudited financial statements, showing a sharp increase in net loss to $5.6 million due to higher clinical trial expenses. The company successfully raised capital through ATM offerings, but also disclosed material weaknesses in ", "url": "https://www.minichart.com.sg/2026/06/05/greenwich-lifesciences-inc-q1-2026-quarterly-report-financials-risk-factors-and-disclosure-highlights/", "source_name": "Minichart", "published_at": "2026-06-05T00:36:15", "published_display": "05 Jun 2026 00:36", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/greenwich-lifesciences-says-audit-2025-104846963.html", "source_name": "MT Newswires", "published_at": "2026-06-01T10:48:46+00:00", "published_display": "01 Jun 2026 10:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Provides Update Regarding Form 10-K Filing", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/greenwich-lifesciences-provides-regarding-form-100000046.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T10:00:00+00:00", "published_display": "01 Jun 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GREENWICH LIFESCIENCES ($GLSI) Releases Q4 2025 Earnings | GLSI Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPMTQ5SWdHY3FCVUhQb1BiQUp4d2lMRVhRVnpsZ0dUWEhwTmFHUHJGYzRjNm1ZWVdYQzBxMzVJR2oxR0dJN3p1QlRYUWhLZV8tVldMeDdDQk50eDRpVWVtR0h1bDI1MmZaWkE0NVRTc1dLbjh2bUdUM1M0LTltN2YxYWJNazRHZkppMExVZHRFb0NKR0ZNQVYtMHJCVQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOeTdPY1hMcGFJcjI3OFdTLWJJUmsyV0IzWTRlZ0Y5dUNnUzRBaEZKQ2VlZ1d1c1MxMTl6VE9qOXJNWWhrOTJYanp0NVAxZ0NONHhjeFJWbHUxYVlDV05kNzVsMkFwT1JyeU1mLURubVFsR0s5ZkZ6UUdZcjRqZVZqdHBGSGk2aGMtUEN2VGhFcUZrOUhQbjM1UlBPbng0TnpoU3c0UnRzUi1NaXVJYXRLSjZWeEZLbFotTE5OaExyRWtUVkJxTkpBX2pTMHB6cld2aHdpLVNORHNpN1E0Uzl5dmtwU3VVOVFERmlzQ0hmWHhUaXc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNa01PSE9fVlh1NGl0YXBRN1JuOHlZRm1XdS1YajRhWmNwT0NGc21OZkMwcXc0bWxOWjlSQVNLXzFKeGJBdW16RFNidXNEN0tvOUFNUXhybnp4d01TSm9uSTVyc2M4X0hWcmRrck9Db1cyazA3RkNXUm9ZMmdlTmljbVJKTWh0ODRDYTVTZ25LdVhTbTQwUHFtMDBUMC1ONGlLcHRGUEk4YTRmQW1oWmV2VExQLXZ0eGM?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQMWxOUjMxdXBOTDdVV1YzeTYyWmZ2M2l3R19IOGNHWk52SDYxMXhKUWZsc3BHaTdETFdPbTZkUk5QbXJzUmRlTm91ZjRXVFZaWGxKQ3l5b2pud3FqVERnMGhIdi16bldidUZwNUlFX2gtV01BSk9ySHk2ZGhWclBEeE5NdmNNN1pQS2FMU0plS1ZzMEpvZUdHQjZ1WFhLc2MwblZaZnZEMm16WjRtUF9r?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves commercial GP2 lot for Greenwich\u2019s breast cancer trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNSUtkOHc4ZVcxNFlYTmIzLTVlUlVoeW5FcDVlVVVfUzZvWDBrQlF3NHNLZS1SMkFPT3ZCYlRqMHJRZTJ6cDZ3aXdnMjFLYmRTRE0tUnhrd3lBRW5xN2ZNZGh2TDF5eURJczNyeHJKSGFjUk5wMl9FWUJYbkpBQ1hBdGRRb0l0UVB2azFLZ0tEbnA5YWN0QkE4dVZ4cE8xa2hBQ1JJUno5bVBzemxMNVJPeTJTN0dXMzhGcTUwUzB1Rlg?oc=5", "source_name": "Investing.com", "published_at": "2026-01-22T08:00:00+00:00", "published_display": "22 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Snehal Patel Buys Handful Of Shares In Greenwich LifeSciences", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences, Inc. Announces Extension of Lock-Up Period for Shares to September 30, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQYlFKYVYtZHpFSnpfNWlOTng1alVpZ3JwcWgzdjBsOEtLbXFVUzJqV0VoMzZaQUJRdk5wc1VpTWhLUHIxbm11TnFvMFlrdUVVLWdZVmRzN0lTQkxweloxZUVtTG14VzNJQUFOVHd5MTBRUE9SRWFfdnFPQ2ozTlc2aFZiTHRyU3o4ZGVYWHBabkx3WGZYOWxTdm5Ba05nak8wdElqOGJ5M2ZDbWwydG1zbUd3VWZYQzRESEQzQktGRGtOYjRpTHI5NWowTURtcEw4MHc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQT1F5YmFzejhtbFhVQUo2R0x5YURONU1pWlJWOGtmUXJLeGFGaFQtb0RTU0l4U2dlbDl2VTI5RzBiMVNLMTZsZTJhNnVpWFFNX2l5Q0FhdFMyR1MxMjYxdzJSbGVRNC0wSFpjWXR6UFk0Yk5hSFNvbmlkd1ZncUZkZGJROFJMTDlpVWpzYlhXWnI3VzVPQ0szLUlOc1lLWGJKMGhQUmYzM0QwVHllMlFVUDJabW1hSFpaeElNRHZsc0Y?oc=5", "source_name": "Stock Titan", "published_at": "2024-03-13T07:00:00+00:00", "published_display": "13 Mar 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 52, "sentiment_summary": {"positive": 16, "negative": 7, "neutral": 29, "score": 56, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 14.45, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.4, "count": 8}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 19.8, "latest_week": "2026-07-10", "one_week_move": -10.0, "four_week_move": -17.7, "twelve_week_move": -28.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.309868, "market_dynamics_buy_signal": false, "relative_strength": -6.166043, "fair_value_gap": 39.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 43.3008, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.0% over one week, -17.7% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "Stock Titan", "count": 3}, {"label": "Stock Traders Daily", "count": 3}, {"label": "Finviz", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 14}, {"label": "Regulatory and legal", "count": 8}, {"label": "Guidance", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-10.0% over one week, -17.7% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Greenwich LifeSciences Says EU Regulator Approves Combination of HLA Patients in Phase 3 Trial"}], "updated_at": "2026-07-17T06:19:16.571453+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}